Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;37(2):435-436.
doi: 10.1002/mds.28909. Epub 2022 Jan 17.

Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)

Carsten Buhmann  1 , Susanne Lezius  2 , Monika Pötter-Nerger  1 , Christian Gerloff  1 , Jens Kuhle  3 , Chi-Un Choe  1
Affiliations
Comment

Age-Adjusted Serum Neurofilament Predicts Cognitive Decline in Parkinson's Disease (MARK-PD)

Carsten Buhmann et al. Mov Disord. 2022 Feb.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Aamodt WW, Waligorska T, Shen J, et al. Neurofilament light chain as a biomarker for cognitive decline in Parkinson disease. Mov Disord 2021. https://doi.org/10.1002/mds.28779
    1. Niemann L, Lezius S, Maceski A, et al. Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD). Parkinsonism Relat Disord 2021;90:44-48.
    1. Lin CH, Li CH, Yang KC, et al. Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 2019;93(11):e1104-e1111.
    1. Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14(10):577-589.
    1. Mollenhauer B, Dakna M, Kruse N, et al. Validation of serum Neurofilament light chain as a biomarker of Parkinson's disease progression. Mov Disord 2020;35(11):1999-2008.

Substances

LinkOut - more resources